Nanoparticles (NPs) have been used for decades as drug delivery systems (DDSs) due to their unique properties, including the ability to adsorb and encapsulate molecules. Controlling the delivery of cancer drugs can overcome the lack of chemotherapy selectivity and increase the concentration of the drug in specific tissues, which enhances the efficacy and reduces side effects. Among the different platforms of NPs that can be used for DDS, liposomes have the ability to carry hydrophobic and hydrophilic molecules and reported as one of the lowest toxicity NPs in vivo. Liposomal formulations usually prepared by conventional methods such as film hydration. Conventional methods have many limitations restricting their use for drug delivery systems, such as large particle size, high polydispersity index (PDI), and batch-to-batch variability. Microfluidics (MF) is a novel technology used to produce liposomal formulations by offering high control of different parameters, including total volumetric flow rate (TFR) and flow rate ratio (FRR). Technology uses microscopic channels that provide the laminar flow of fluids. This type of flow enhances the mixing quality and provides the same mixing conditions over time, which reduced batch to batch variation. The current work aims to produce liposomes with dimensions < 200 nm, low PDI, good stability, and high encapsulation efficiency (EE) of anticancer drugs.
|Publication status||Published - 25 May 2022|
|Event||2022 UKICRS Workshop & Symposium - Manchester, United Kingdom|
Duration: 09 Jun 2022 → 10 Jun 2022
|Conference||2022 UKICRS Workshop & Symposium|
|Period||09/06/2022 → 10/06/2022|
- Drug Delivery
- Cancer therapy